Equity Field Notes from temporal sources

[DanWebzster]

TOCA has an ongoing Ph3 genetic therapy to treat recurrent high grade glioma.

There were 127 patients in the Ph1 study. Survival was prolonged relative to historical benchmarks. Also, there were 5 complete responses.

Treatment has been designated a breakthrough therapy. As a result, no data analysis was published on the Ph2 portion of the study.

As of Q4/2017, cash = $88.7mn. Projected spending for 2018 is $50mn

If Ph3 is a success, I will consider buying the first pullback on first trading day after the read-out and making a decision to about how much to hold based on the MC, at the time.